Ovid Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

• Ovid Therapeutics Inc OVID.OQ reported quarterly adjusted earnings of 6 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -13 cents. The mean expectation of ten analysts for the quarter was for a loss of 12 cents per share. Wall Street expected results to range from -18 cents to -6 cents per share.

• Revenue rose 844.7% to $718.00 thousand from a year ago; analysts expected $13.33 thousand.

• Ovid Therapeutics Inc's reported EPS for the quarter was 6 cents​.

• The company reported quarterly net income of $9.66 million.

• Ovid Therapeutics Inc shares had risen by 23.3% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 10 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Ovid Therapeutics Inc is $4.50, about 55.3% above its last closing price of $2.01

This summary was machine generated from LSEG data March 18 at 10:30 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)